The Trump administration’s dramatic reworking of U.S. public-health agencies’ approach to vaccines is creating a difficult and unpredictable situation for drugmakers.
The review draws the formal regulatory distinction: gene therapy involves the deliberate and permanent alteration of a patient's genome. mRNA vaccines do not ...